Childhood nosocomial viral acute respiratory tract infections in teaching hospital Anuradhapura, Sri Lanka

What is the optimal country for minimum COVID-19 morbidity and mortality rates?

The SARS-CoV-2 is a deceptive virus. Despite the remarkable progress in genetic sequencing and subsequent vaccine development, the world continues to grapple with the ominous threats of rapidly appearing SARS-CoV-2 variants. The objective of this manuscript is to rank world countries based on the anticipated scope of COVID-19 morbidity and mortality, measured in terms of prevalence per 1 million persons, from the lowest to the highest. The ranking of 162 countries is based on predictions of empirical models, which include three explanatory variables: hospital beds per thousand persons, population density, and the median age of the country's population. Referring to the COVID-19 scope of morbidity, the lowest likelihood of infection is obtained in Niger and Mali, where the dominant characteristic is the young median age (15.1-16.4 years). Referring to the COVID-19 scope of mortality, the lowest likelihood is obtained in Singapore. For Singapore, the dominant feature is the high population density. The optimal solution is intensive vaccination campaigns in the initial phase of the pandemic, particularly among countries with low GDP per capita. Yet, vaccinations may work only where the personal immune system is healthy and thus respond by creating antibodies to the SARS-CoV2 virus. Referring to populations that lack the natural protection of the healthy immune system and thus cannot be vaccinated (e.g., old people, cancer patients undergoing chemotherapy treatments), a complementary solution might be coordination between countries and the establishment of field hospitals, testing laboratories, isolation of areas, humanitarian aid-in the same manner of treatment in other disasters like earthquakes.

Nosocomial RSV-related In-hospital Mortality in Children <5 Years: A Global Case Series

BACKGROUND

According to the World Health Organization, the global burden of nosocomial infections is poorly characterized as surveillance systems are lacking. Nosocomial infections occur at higher rates in low- and lower-middle-income countries (LMICs) than in high-income countries (HICs). Current global RSV burden estimates are largely based on community-acquired infection. We aimed to characterize children with nosocomial RSV-related mortality and to understand the potential impact of RSV immunization strategies.

MATERIALS

RSV GOLD is a global registry of children younger than 5 years who died with laboratory-confirmed RSV infection. We compared clinical and demographic characteristics of children with nosocomial and community-acquired RSV in-hospital mortality.

RESULTS

We included 231 nosocomial and 931 community-acquired RSV-related in-hospital from deaths from 65 countries. Age at death was similar for both groups (5.4 vs. 6 months). A higher proportion of nosocomial deaths had comorbidities (87% vs. 57%; P < 0.001) or was born preterm (46% vs. 24%; P < 0.001) than community-acquired deaths. The proportion of nosocomial deaths among all RSV deaths was lower in LMICs than in upper-middle-income countries (UMICs) and HICs (12% vs. 18% and 26%, respectively).

CONCLUSIONS

This is the first global case series of children dying with nosocomial RSV infection. Future infant-targeted immunization strategies could prevent the majority of nosocomial RSV-related deaths. Although nosocomial RSV deaths are expected to occur at highest rates in LMICs, the number of reported nosocomial RSV deaths was low in these countries. Hospital-based surveillance is needed to capture the full burden of nosocomial RSV mortality in LMICs.

Epidemiology and Seasonality of Childhood Respiratory Syncytial Virus Infections in the Tropics

Infections caused by respiratory syncytial virus (RSV) are a major cause of morbidity and mortality in young children worldwide. Understanding seasonal patterns of region-specific RSV activity is important to guide resource allocation for existing and future treatment and prevention strategies. The decades of excellent RSV surveillance data that are available from the developed countries of the world are incredibly instructive in advancing public health initiatives in those regions. With few exceptions, these developed nations are positioned geographically across temperate regions of the world. RSV surveillance across tropical regions of the world has improved in recent years, but remains spotty, and where available, still lacks the necessary longitudinal data to determine the amount of seasonal variation expected over time. However, existing and emerging data collected across tropical regions of the world do indicate that patterns of infection are often quite different from those so well described in temperate areas. Here, we provide a brief summary regarding what is known about general patterns of RSV disease activity across tropical Asia, Africa and South America, then offer additional country-specific details using examples where multiple reports and/or more robust surveillance data have become available.

Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middle-income countries

INTRODUCTION

Respiratory syncytial virus (RSV) causes approximately 120,000 deaths annually in children <5 years, with 99% of fatalities occurring in low- and middle-income countries (LMICs).

AREAS COVERED

There are numerous RSV interventions in development, including long-acting monoclonal antibodies, vaccines (maternal and child) and treatments which are expected to become available soon. We reviewed the key challenges and issues that need to be addressed to maximize the impact of these interventions in LMICs. The epidemiology of RSV in LMICs was reviewed (PubMed search to 30 June 2020 inclusive) and the need for more and better-quality data, encompassing hospital admissions, community contacts, and longer-term respiratory morbidity, emphasized. The requirement for an agreed clinical definition of RSV lower respiratory tract infection was proposed. The pros and cons of the new RSV interventions are reviewed from the perspective of LMICs.

EXPERT OPINION

We believe that a vaccine (or combination of vaccines, if practicable) is the only viable solution to the burden of RSV in LMICs. A coordinated program, analogous to that with polio, involving governments, non-governmental organizations, the World Health Organization, the manufacturers and the healthcare community is required to realize the full potential of vaccine(s) and end the devastation of RSV in LMICs.